L-Serine is a conditionally essential amino acid naturally synthesized in the human body from 3-phosphoglycerate, a glycolytic intermediate, primarily in astrocytes in the brain. It is classified as conditionally essential because synthesis may be insufficient under high metabolic demand, neurological disease, or certain genetic enzyme deficiencies (e.g., 3-phosphoglycerate dehydrogenase deficiency). Beyond its role as a protein building block, serine functions as a metabolic hub, feeding into one-carbon metabolism, de novo sphingolipid synthesis, and phospholipid production.

L-Serine exerts its neurological effects primarily through two downstream pathways: conversion to D-serine (via serine racemase), which acts as a co-agonist at NMDA glutamate receptors and is essential for synaptic plasticity and memory consolidation; and conversion to phosphatidylserine and sphingomyelin, which are structural phospholipids critical for neuronal membrane integrity and signaling. Serine also contributes to the folate one-carbon cycle, supporting methylation reactions that regulate gene expression and neurotransmitter synthesis. Deficiency in brain serine supply has been linked to dysregulation of D-serine signaling and aberrant sphingolipid accumulation, both implicated in neurodegenerative disease.

L-Serine is most commonly available as a free-form amino acid powder or capsule. Powder form allows flexible dosing and is well absorbed orally. In clinical research settings, particularly ALS and rare pediatric neurological disorders, intravenous administration has been studied. Phosphatidylserine supplements (derived from soy or sunflower lecithin) are a related but distinct product that provides serine in a phospholipid-bound form rather than as free amino acid.

• ALS (Amyotrophic Lateral Sclerosis) — neuroprotective/disease-modifying (investigational)
• Hereditary sensory and autonomic neuropathy type 1 (HSAN1)
• Cognitive decline / memory support
• Sleep quality
• Childhood serine biosynthesis disorders

• Deoxy-sphingolipid accumulation in HSAN1 mutation carriers (evidence from Fridman et al., 2019 RCT)

• Soy protein / Edamame — Soy protein is among the highest dietary sources of L-Serine by amino acid composition, with roughly 5–6 g of serine per 100 g of protein, making it a practical whole-food source.
• Eggs (egg white) — Egg whites contain substantial serine (~9 g serine per 100 g protein), and are a highly bioavailable complete protein source readily accessible in most diets.
• Meat (beef, chicken, turkey) — Animal proteins, particularly lean beef and poultry, provide serine at 4–5 g per 100 g protein and are complete protein sources with high bioavailability.
• Dairy (cottage cheese, Greek yogurt) — Casein and whey proteins found in dairy contain meaningful amounts of serine and also provide phosphatidylserine precursors, supporting both direct serine intake and downstream phospholipid synthesis.
• Nuts and seeds (peanuts, sesame, sunflower seeds) — Nuts and seeds are moderate plant-based sources of serine and also provide phosphatidylserine-rich lipid fractions, supporting serine-dependent neurological pathways from multiple angles.

• Nausea or gastrointestinal discomfort (most common, dose-dependent)
• Loose stools or diarrhea at high doses (>15 g/day)
• Mild sedation or fatigue (reported anecdotally, possibly via glycine conversion)
• Headache (rare, not consistently documented across trials)
• Theoretical risk of exacerbating certain metabolic disorders involving serine catabolism (relevant only in specific enzyme deficiencies)

• Recommended daily: General cognitive/neurological support: 3–7 g/day in divided doses. HSAN1 (therapeutic, under medical supervision): 400 mg/kg/day. ALS clinical trial dosing: 15–30 g/day (medical supervision required). Childhood serine biosynthesis disorders: up to 600 mg/kg/day (specialist-directed).
• Best time of day: Divide doses across 2–3 times daily to maintain steady plasma levels. For sleep support, some evidence supports taking a portion of the dose (1–3 g) 30–60 minutes before bedtime, consistent with glycine-pathway research.
• With or without food: Can be taken with or without food. Taking with a small meal or protein-containing snack may improve tolerability and reduce gastrointestinal discomfort at higher doses.
• Time to effect: Metabolic markers (e.g., deoxy-sphingolipid reduction in HSAN1) may normalize within 4–8 weeks. Cognitive and sleep benefits, where reported, typically emerge after 2–4 weeks of consistent use. Neuroprotective effects in progressive disease may require months to assess.
• How long to take it: For therapeutic conditions (HSAN1, ALS), long-term continuous use under physician supervision is standard. For general cognitive support, a 3-month trial is reasonable to assess benefit; no established cycling protocol is required, but periodic reassessment is advisable.